我們已在上線！ 進一步了解
NVO圖示

Novo Nordisk
NVO

38.83 USD
-0.39
0.99%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
38.73
-0.10
0.26%
1天
-0.99%
5天
-0.05%
1個月
-6.9%
3個月
-24.57%
6個月
-5.13%
今年迄今
-25.88%
1年
-30.77%
5年
-24.92%
10年
92.51%
 

關於： With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

員工： 69,500

醫療保健 藥品製造商－一般

新聞

正面
中性
負面
市場情緒 3個月
正面 43%
中性 24.7%
負面 32.3%
正面
The Motley Fool
16 小時前
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
The study used Novo Nordisk's semaglutide to arrive at its results. The news should only cause the market for GLP-1 drugs to grow faster.
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
中性
Zacks Investment Research
3 天前
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
In the latest trading session, Novo Nordisk (NVO) closed at $38.06, marking a -1.35% move from the previous day.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
正面
The Motley Fool
3 天前
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira. Novo Nordisk maintains a dominant lead in the rapidly expanding metabolic health market through its blockbuster obesity treatments.
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
負面
Zacks Investment Research
4 天前
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
正面
The Motley Fool
6 天前
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb provides high free cash flow and a deep oncology pipeline at a modest valuation. Novo Nordisk dominates the obesity and diabetes markets with exceptional net margins and steady growth.
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
中性
The Motley Fool
8 天前
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
UBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaround story. Yee sees Novo Nordisk turning its business around, but believes it could take some time.
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
中性
Market Watch
8 天前
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
Rapid weight loss can lead to issues with bone quality, particularly in older adults.
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
正面
Seeking Alpha
9 天前
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium
Novo Nordisk is rated Buy versus Hold for Eli Lilly, anchored by a compelling valuation discount to big pharma peers. NVO trades at ~11.2x 2027 earnings, a ~26% discount to peer median, despite consensus growth rates in line with peers and a robust yield. The investment case does not require a rerating; ~10% annual returns are achievable if current discounted valuations hold and yield continues.
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium
負面
Zacks Investment Research
9 天前
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
Novo Nordisk (NVO) reached $38.26 at the closing of the latest trading day, reflecting a +1.95% change compared to its last close.
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
正面
Zacks Investment Research
9 天前
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
查看新聞排名
價格圖表採用Lightweight Charts™實作